COMMENTARY

• SCARDA Now Up and Running: Will It Lead to a Recovery in Japan’s Ability to Develop Vaccines?
  April 22, 2022

• Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
  April 19, 2022

• Drug Makers Forced to Make Tough Decisions on AG Strategies: Licensing Profits or Losses on Early G1 Cuts?
  April 8, 2022

• Drug Makers Guard against Price Adjustment Rate, Off-Year Revision Debates: Jiho Poll
  March 16, 2022

• Drug Makers in Japan Increasingly Tested for Product Prowess, Rather than Marketing Ability
  February 25, 2022

• Will New Economic Security Bill Contribute to Ensuring Stable Drug Supplies?
  February 16, 2022

• JPMA Chief’s Comments to Endorse Coverage Review Send Ripples through Industry
  February 3, 2022

• Significance and Challenges around Proposed Emergency Approval Scheme, Eyes on Diet Debate
  January 17, 2022

• Japan Unlikely to Introduce Medical Fee Incentives for Hospital Formularies in FY2022 Reform
  December 20, 2021

• Public-Private Collaboration Needed to Refine SaMD Regulatory System
  November 26, 2021

• MOF, MHLW Push Conflicting Narratives on Drug Cost Control; Macroeconomic Indexing Is a Major Focus Too
  November 16, 2021

• SGLT2 Inhibitors, Entresto Could Change Paradigm of Treatment of Heart Failure: JHFS Annual Confab
  October 26, 2021

• LDP’s Pharma Study Group at Critical Juncture as Kishida Vows to Rectify Power Balance, Kingpins Retire
  October 19, 2021

• Drug Makers Downsizing Sales Forces to Increase Efficiency; Launch of Redundancy Programs to Be Continued
  October 15, 2021

• Pharma on Alert for Possible Repeat of Minister Deal on Drug Pricing Reform
  October 13, 2021

• 5 Companies Developing Japan-Made COVID-19 Jabs Face Challenges in Subject Enrollment, Trial Designs
  September 29, 2021

• CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
  August 3, 2021

• Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
  July 12, 2021

• Updated Heart Failure Guidelines Position Entresto, SGLT2 Inhibitors as New Treatment Strategy Options
  June 22, 2021

• Battle Looming over 2% Adjustment Rate as New Honebuto Paper Nears Completion
  June 1, 2021

ページ